Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition

Clinical Science

Volumn 118, Issue 1, 2010, Pages 31-41

  Kirby, Mark ^a   Yu, Denise M T ^b   O'Connor, Stephen P ^a   Gorrell, Mark D ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b University of Sydney   (Australia)

Author keywords

Diabetes; Dipeptidyl peptidase 4; Enzyme inhibition; Immunity; Selectivity

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIPEPTIDYL PEPTIDASE IX; DIPEPTIDYL PEPTIDASE VIII; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; INCRETIN; SAXAGLIPTIN; SEPRASE; SITAGLIPTIN; UNCLASSIFIED DRUG; VILDAGLIPTIN;

DRUG BLOOD LEVEL; DRUG SELECTIVITY; ENZYME ACTIVE SITE; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME SUBSTRATE; GLUCOSE METABOLISM; HUMAN; IC 50; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TOXICITY TESTING;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DIPEPTIDYL-PEPTIDASES AND TRIPEPTIDYL-PEPTIDASES; DRUG DISCOVERY; HUMANS; HYPOGLYCEMIC AGENTS; PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70549096922     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20090047     Document Type: Review

References (55)

1. Barnett, A. (2006) DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int. J. Clin. Pract. 60, 1454-1470
2. Toft-Nielsen, M. B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K. and Holst, J. J. (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 86, 3717-3723
3. Amori, R. E., Lau, J. and Pittas, A. G. (2007) Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA, J. Am. Med. Assoc. 298, 194-206
4. Raz, I., Chen, Y., Wu, M., Hussain, S., Kaufman, K. D., Amatruda, J. M., Langdon, R. B., Stein, P. P. and Alba, M. (2008) Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr. Med. Res. Opin. 24, 537-550
5. Drucker, D. J. (2003) Glucagon-like peptide-1 and the islet β-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 144, 5145-5148
6. Meier, J. J. (2008) Beta cell mass in diabetes: a realistic therapeutic target? Diabetologia 51, 703-713
7. Gorrell, M. D. and Yu, D. M. (2005) Diverse functions in a conserved structure: the dipeptidyl peptidase IV gene family. In Trends in Protein Research (Robinson, J. W., ed.), pp. 1-79, Nova Biomedical Books, New York
8. Gorrell, M. D. (2005) Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin. Sci. 108, 277-292
9. Abbott, C. A., McCaughan, G. W. and Gorrell, M. D. (1999) Two highly conserved glutamic acid residues in the predicted β propeller domain of dipeptidyl peptidase IV are required for its enzyme activity. FEBS Lett. 458, 278-284
10. Chen, T., Ajami, K., McCaughan, G. W., Gai, W. P., Gorrell, M. D. and Abbott, C. A. (2006) Molecular characterization of a novel dipeptidyl peptidase like 2-short form (DPL2-s) that is highly expressed in the brain and lacks dipeptidyl peptidase activity. Biochim. Biophys. Acta 1764, 33-43
11. Gorrell, M. D., Gysbers, V. and McCaughan, G. W. (2001) CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand. J. Immunol. 54, 249-264
12. Rasmussen, H. B., Branner, S., Wiberg, F. C. and Wagtmann, N. (2003) Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat. Struct. Biol. 10, 19-25
13. Engel, M., Hoffmann, T.,Wagner, L., Wermann, M., Heiser, U., Kiefersauer, R., Huber, R., Bode, W., Demuth, H. U. and Brandstetter, H. (2003) The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc. Natl. Acad. Sci. U.S.A. 100, 5063-5068
14. Metzler, W. J., Yanchunas, J., Weigelt, C., Kish, K., Klei, H. E., Xie, D., Zhang, Y., Corbett, M., Tamura, J. K., He, B. et al. (2008) Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation. Protein Sci. 17, 240-250
15. Marguet, D., Baggio, L., Kobayashi, T., Bernard, A. M., Pierres, M., Nielsen, P. F., Ribel, U., Watanabe, T., Drucker, D. J. and Wagtmann, N. (2000) Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. U.S.A. 97, 6874-6879
16. Busso, N., Wagtmann, N., Herling, C., Chobaz-Péclat, V., Bischof-Delaloye, A., So, A. and Grouzmann, E. (2005) Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. Am. J. Pathol. 166, 433-442
17. Wang, X. M., Yao, T. W., Nadvi, N. A., Osborne, B., McCaughan, G. W. and Gorrell, M. D. (2008) Fibroblast activation protein and chronic liver disease. Front. Biosci. 13, 3168-3180
18. Levy, M. T., McCaughan, G. W., Marinos, G. and Gorrell, M. D. (2002) Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection. Liver 22, 93-101
19. Aertgeerts, K., Levin, I., Shi, L., Snell, G. P., Jennings, A., Prasad, G. S., Zhang, Y., Kraus, M. L., Salakian, S., Sridhar, V. et al. (2005) Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein α. J. Biol. Chem. 280, 19441-19444
20. Edosada, C. Y., Quan, C., Wiesmann, C., Tran, T., Sutherlin, D., Reynolds, M., Elliott, J. M., Raab, H., Fairbrother, W. and Wolf, B. B. (2006) Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity. J. Biol. Chem. 281, 7437-7444
21. Ajami, K., Abbott, C. A., McCaughan, G. W. and Gorrell, M. D. (2004) Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochim. Biophys. Acta 1679, 18-28
22. Maes, M. B., Dubois, V., Brandt, I., Lambeir, A. M., Van der Veken, P., Augustyns, K., Cheng, J. D., Chen, X., Scharpé, S. and De Meester, I. (2007) Dipeptidyl peptidase 8/9-like activity in human leukocytes. J. Leukocyte Biol. 81, 1252-1257
23. Schade, J., Stephan, M., Schmiedl, A., Wagner, L., Niestroj, A. J., Demuth, H. U., Frerker, N., Klemann, C., Raber, K. A., Pabst, R. and von Hörsten, S. (2008) Regulation of expression and function of dipeptidyl peptidase 4 (DP4), DP8/9, and DP10 in allergic responses of the lung in rats. J. Histochem. Cytochem. 56, 147-155
24. Bjelke, J. R., Christensen, J., Nielsen, P. F., Branner, S., Kanstrup, A. B., Wagtmann, N. and Rasmussen, H. B. (2006) Dipeptidyl peptidases 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IV. Biochem. J. 396, 391-399
25. Ajami, K., Pitman, M. R., Wilson, C. H., Park, J., Menz, R. I., Starr, A. E., Cox, J. H., Abbott, C. A., Overall, C. M. and Gorrell, M. D. (2008) Stromal cell-derived factors 1a and 1b, 4 inflammatory protein-10 and interferon-inducible T cell 5 chemo-attractant are novel substrates of dipeptidyl peptidase 8. FEBS Lett. 582, 819-825
26. Plamboeck, A., Holst, J. J., Carr, R. D. and Deacon, C. F. (2005) Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 48, 1882-1890
27. Rossi, D. and Zlotnik, A. (2000) The biology of chemokines and their receptors. Annu. Rev. Immunol. 18, 217-242
28. Kirby, M. S., Dorso, C., Wang, A., Weigelt, C., Kopcho, L., Hamann, L. and Marcinkeviciene, J. (2008) In vitro enzymologic characteristics of saxagliptin, a highly potent and selective DPP4 inhibitor with 'slow binding' characteristics. Clin. Chem. Lab. Med. 46, A29
29. Biftu, T., Scapin, G., Singh, S., Feng, D., Becker, J.W., Eiermann, G., He, H., Lyons, K., Patel, S., Petrov, A. et al. (2007) Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin. Bioorg. Med. Chem. Lett. 17, 3384-3387
30. Feng, J., Zhang, Z., Wallace, M. B., Stafford, J. A., Kaldor, S. W., Kassel, D. B., Navre, M., Shi, L., Skene, R. J., Asakawa, T. et al. (2007) Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J. Med. Chem. 50, 2297-2300
31. Rummey, C. and Metz, G. (2007) Homology models of dipeptidyl peptidases 8 and 9 with a focus on loop predictions near the active site. Proteins 66, 160-171
32. Park, J., Knott, H. M., Nadvi, N. A., Collyer, C. A., Wang, X. M., Church, W. B. and Gorrell, M. D. (2008) Reversible inactivation of human dipeptidyl peptidases 8 and 9 by oxidation. Open Enzyme Inhibition J. 1, 52-60
33. Kang, N. S., Ahn, J. H., Kim, S. S., Chae, C. H. and Yoo, S. E. (2007) Docking-based 3D-QSAR study for selectivity of DPP4, DPP8, and DPP9 inhibitors. Bioorg. Med. Chem. Lett. 17, 3716-3721
34. Lu, I. L., Lee, S. J., Tsu, H., Wu, S. Y., Kao, K. H., Chien, C. H., Chang, Y. Y., Chen, Y. S., Cheng, J. H., Chang, C. N. et al. (2005) Glutamic acid analogues as potent dipeptidyl peptidase IV and 8 inhibitors. Bioorg. Med. Chem. Lett. 15, 3271-3275
35. Jiaang, W. T., Chen, Y. S., Hsu, T., Wu, S. H., Chien, C. H., Chang, C. N., Chang, S. P., Lee, S. J. and Chen, X. (2005) Novel isoindoline compounds for potent and selective inhibition of prolyl dipeptidase DPP8. Bioorg. Med. Chem. Lett. 15, 687-691
36. Van der Veken, P., De Meester, I., Dubois, V., Soroka, A., Lambeir, A. M., Chen, X., Haemers, A., Scharpé, S., De Meester, I. and Augustyns, K. (2008) Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: identification of dipeptide derived leads. Bioorg. Med. Chem. Lett. 18, 4154-4158
37. Van Goethem, S., Van der Veken, P., Dubois, V., Soroka, A., Lambeir, A. M., Chen, X., Haemers, A., Scharpé, S., De Meester, I. and Augustyns, K. (2008) Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 2: isoindoline containing inhibitors. Bioorg. Med. Chem. Lett. 18, 4159-4162
38. Lankas, G. R., Leiting, B., Roy, R. S., Eiermann, G. J., Beconi, M. G., Biftu, T., Chan, C. C., Edmondson, S., Feeney, W. P., He, H. et al. (2005) Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 54, 2988-2994
39. Wang, X. M., Yu, D. M., McCaughan, G. W. and Gorrell, M. D. (2005) Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology 42, 935-945
40. Yu, D. M., Wang, X. M., McCaughan, G. W. and Gorrell, M. D. (2006) Extraenzymatic functions of the dipeptidyl peptidase IV-related proteins DP8 and DP9 in cell adhesion, migration and apoptosis. FEBS J. 273, 2447-2460
41. Pethiyagoda, C. L., Welch, D. R. and Fleming, T. P. (2000) Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells. Clin. Exp. Metastasis 18, 391-400
42. Wesley, U. V., Tiwari, S. and Houghton, A. N. (2004) Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells. Int. J. Cancer 109, 855-866
43. 1, adhesion to extracellular matrix, and tumorigenicity of T-anaplastic large cell lymphoma Karpas 299. Cancer Res. 65, 6950-6956
44. Wesley, U. V., Albino, A. P., Tiwari, S. and Houghton, A. N. (1999) A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J. Exp. Med. 190, 311-322
45. Weihofen, W. A., Liu, J., Reutter, W., Saenger, W. and Fan, H. (2004) Crystal structure of CD26/dipeptidylpeptidase IV in complex with adenosine deaminase reveals a highly amphiphilic interface. J. Biol. Chem. 279, 43330-43335
46. Burkey, B. F., Hoffmann, P. K., Hassiepen, U., Trappe, J., Juedes, M. and Foley, J. E. (2008) Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes Obes. Metab. 10, 1057-1061
47. Rosenblum, J. S., Minimo, L. C., Yongsheng, L., Wu, J. and and Kozarich, J. W. (2008) The case against GI toxicity from acute DPP8/9 inhibition. Diabetes 56, A138
48. Steeg, C., Hartwig, U. and Fleischer, B. (1995) Unchanged signaling capacity of mutant CD26/dipeptidylpeptidase IV molecules devoid of enzymatic activity. Cell. Immunol. 164, 311-315
49. Coburn, M. C., Hixson, D. C. and Reichner, J. S. (1994) In vitro immune responsiveness of rats lacking active dipeptidylpeptidase IV. Cell. Immunol. 158, 269-280
50. Tanaka, S., Murakami, T., Horikawa, H., Sugiura, M., Kawashima, K. and Sugita, T. (1997) Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV. Int. J. Immunopharmacol. 19, 15-24
51. Vora, K. A., Porter, G., Peng, R., Cui, Y., Pryor, K., Eiermann, G. and Zaller, D. M. (2009) Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses. BMC Immunol. 10, 19
52. Christopher, R. J., Davenport, J. M., Gwaltney, S., Kaldor, S., Kassel, D., Lee, B., Shi, L., Stafford, J., Xu, R. and Zhang, Z. (2006) Pharmacokinetic and pharmacodynamic profiles of SYR-322, a novel inhibitor of dipeptidyl peptidase-IV, in rats, dogs, and monkeys. Diabetes 55, 452-P
53. Augeri, D. J., Robl, J. A., Betebenner, D. A., Magnin, D. R., Khanna, A., Robertson, J. G., Wang, A., Simpkins, L. M., Taunk, P., Huang, Q. et al. (2005) Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 48, 5025-5037
54. Kim, D., Wang, L., Beconi, M., Eiermann, G. J., Fisher, M. H., He, H., Hickey, G. J., Kowalchick, J. E., Leiting, B., Lyons, K. et al. (2005) (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo [4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan- 2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 48, 141-151
55. Villhauer, E. B., Brinkman, J. A., Naderi, G. B., Burkey, B. F., Dunning, B. E., Prasad, K., Mangold, B. L., Russell, M. E. and Hughes, T. E. (2003) 1-(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano- (S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem. 46, 2774-2789